{"schema_version":"secwatch.filing_event.v1","accession":"0001555280-24-000247","form_type":"8-K","ticker":"ZTS","cik":"0001555280","company_name":"Zoetis Inc.","filed_at":"2024-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.940458+00:00","generated_at":"2026-06-03T00:27:09.692641+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Zoetis Q1 revenue $2.2B (+10% reported, +12% operational); adj EPS $1.38, +5% reported","bullets":["Reported net income $599M ($1.31 diluted EPS) +9%; adjusted net income $634M ($1.38 adj EPS) +5% reported, +17% operational.","US segment revenue $1.2B (+16%), driven by Simparica Trio, Apoquel, Cytopoint, Librela, Solensia.","International segment revenue $1.0B (+3% reported, +8% operational); companion animal +14% operational.","FY 2024 guidance raised: revenue $9.05-9.20B, reported EPS $5.34-5.44, adj EPS $5.71-5.81; operational growth 8.5-10.5%.","Company to sell MFA portfolio and buy a manufacturing site in Australia for vaccine development."],"urls":{"canonical":"https://secwatch.observer/filing/0001555280-24-000247","json":"https://secwatch.observer/filing/0001555280-24-000247.json","markdown":"https://secwatch.observer/filing/0001555280-24-000247.md","text":"https://secwatch.observer/filing/0001555280-24-000247.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1555280/000155528024000247/0001555280-24-000247-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1555280/000155528024000247/zts-20240502.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T00:27:09.692641+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ac562e47e32b0a0eb7a5077ae5807d57e5d6169f","claim":"Zoetis Inc. reported first quarter of 2024 results: revenue $2.2 billion, net income $599 million, EPS $1.31 per diluted share. Guidance raised.","evidence_excerpt":"Exchange Act, except as expressly set forth by specific reference in such a filing. --- EX-99.1 (EX-99.1) --- Zoetis Announces First Quarter 2024 Results • Reports Revenue of $2.2 Billion, Growing 10%, and Net Income of $599 Million, or $1.31 per Diluted Share, Increasing 9% and 10%, Respectively, on a Reported Basis for First Quarter 2024 • Delivers 12%","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1555280/000155528024000247/0001555280-24-000247-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter of 2024"},{"label":"Revenue","value":"$2.2 billion"},{"label":"Net income","value":"$599 million"},{"label":"EPS","value":"$1.31 per diluted share"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}